Black Friday Savings ! Exclusive Deals on Latest Pharma and Medical Technology Reports.

Explore Now

Hepatitis C Virus Infection Pipeline Insight

DelveInsight’s, “Hepatitis C Virus Infection - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Hepatitis C Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Hepatitis C Virus Infection Understanding

Hepatitis C Virus Infection: Overview

Hepatitis C Virus Infection is a liver infection caused by the Hepatitis C Virus Infection virus. Hepatitis C Virus Infection can range from a mild illness lasting a few weeks to a serious, long-term illness. The Hepatitis C Virus Infection virus (HCV) spreads through contaminated blood. The Hepatitis C Virus Infection virus is a blood borne virus, the most common modes of infection are through exposure to small quantities of blood. This may happen through injection drug use, unsafe injection practices, unsafe health care, transfusion of unscreened blood and blood products, and sexual practices that lead to exposure to blood. Hepatitis C Virus Infection is often described as “acute,” meaning a new infection, or “chronic,” meaning long-term infection. Chronic Hepatitis C Virus Infection can be a serious disease resulting in long-term health problems, including liver damage, liver failure, cirrhosis, liver cancer, and even death. Symptoms may include fever, fatigue, decreased appetite, nausea, vomiting, abdominal pain, dark urine, grey-colored faeces, joint pain and jaundice (yellowing of skin and the whites of the eyes). Treatments for Hepatitis C Virus Infection includes antivirals, like medications called direct-acting antivirals (DAAs) work to fully remove the Hepatitis C Virus Infection virus from the body while helping prevent liver damage.


"Hepatitis C Virus Infection - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis C Virus Infection pipeline landscape is provided which includes the disease overview and Hepatitis C Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Hepatitis C Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis C Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis C Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis C Virus Infection.

Hepatitis C Virus Infection Emerging Drugs Chapters

This segment of the Hepatitis C Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Hepatitis C Virus Infection Emerging Drugs


TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

TG-2349 (Furaprevir) is a HCV protease inhibitor. It is a novel direct acting antivirals for the all-oral treatment of chronic Hepatitis C Virus Infection virus (HCV) infection. The drug has completed Phase III clinical evaluation in combination with DAG181 and Ribavirin for 12 weeks of treatment in HCV Genotype I Infected patients.


SH229: Nanjing Sanhome Pharmaceutical

SH229 is a NS5B inhibitor that is being developed by Nanjing Sanhome Pharmaceutical for the treatment of chronic Hepatitis C Virus Infection virus infection. The drug is currently in Phase II/III clinical studies combined with fixed-dose Daclatasvi dihydrochloride (DCV) tablets for the treatment of Hepatitis C Virus Infection virus infection.

Further product details are provided in the report……..

Hepatitis C Virus Infection: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis C Virus Infection drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Hepatitis C Virus Infection

There are approx. 20+ key companies which are developing the therapies for Hepatitis C Virus Infection. The companies which have their Hepatitis C Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Dongguan HEC TaiGen Biopharmaceuticals.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Hepatitis C Virus Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis C Virus Infection: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis C Virus Infection therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis C Virus Infection drugs.

Hepatitis C Virus Infection Report Insights

  • Hepatitis C Virus Infection Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hepatitis C Virus Infection Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Hepatitis C Virus Infection drugs?
  • How many Hepatitis C Virus Infection drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis C Virus Infection?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis C Virus Infection therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hepatitis C Virus Infection and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Hepatitis C Virus Infection: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

TG-2349: Dongguan HEC TaiGen Biopharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

AT 527: Atea Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

HEC 74647PA: Sunshine Lake Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Prophylactic HCV vaccine: GeneCure Biotechnologies

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Hepatitis C Virus Infection Key Companies

Hepatitis C Virus Infection Key Products

Hepatitis C Virus Infection- Unmet Needs

Hepatitis C Virus Infection- Market Drivers and Barriers

Hepatitis C Virus Infection- Future Perspectives and Conclusion

Hepatitis C Virus Infection Analyst Views

Hepatitis C Virus Infection Key Companies

Appendix

List of Table

Table 1: Total Products for Hepatitis C Virus Infection

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Hepatitis C Virus Infection

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• Dongguan HEC TaiGen Biopharmaceuticals

• Nanjing Sanhome Pharmaceutical

• PharmaEssentia

• HEC Pharm

• Atea Pharmaceuticals

• AllaChem

• HepC

• Sunshine Lake Pharma

• GeneCure Biotechnologies

• Therapure Innovations

• Adaptimmune

• Orgenesis

• Dekk-Tec

Forward to Friend

Need A Quote